Pure Biologics S.A. Logo

Pure Biologics S.A.

Biopharmaceutical company developing novel biological drugs focused on immuno-oncology.

PUR | WAR

Overview

Corporate Details

ISIN(s):
PLPRBLG00010 (+1 more)
LEI:
2594002TXS19AUYHIF82
Country:
Poland
Address:
WROCŁAW LEGNICKA 48E, 54-202 WROCŁAW

Description

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-03 12:35
Informacja o zapisach złożonych na akcje serii P2 w wykonaniu prawa poboru - Co…
Polish 1.2 KB
2025-11-19 17:54
Rejestracja warrantów subskrypcyjnych imiennych serii C uprawniających do objęc…
Polish 798 bytes
2025-11-14 17:33
Skrócone śródroczne sprawozdanie finansowe Pure Biologics S.A. za okres 01.07.2…
Polish 4.1 MB
2025-11-14 17:33
Jednostkowy raport kwartalny Pure Biologics S.A. za 3Q 2025
Polish 1.5 MB
2025-10-27 16:14
Asymilacja akcji serii N Spółki z akcjami znajdującymi się w obrocie na rynku r…
Polish 1.5 KB
2025-10-27 14:05
Rejestracja akcji na okaziciela serii P1 w depozycie papierów wartościowych pro…
Polish 1.1 KB
2025-10-24 18:37
Dopuszczenie i warunkowe wprowadzenie do obrotu na rynku równoległym prowadzony…
Polish 1.5 KB
2025-10-22 11:37
Podjęcie przez Zarząd Spółki uchwały w sprawie ustalenia ceny emisyjnej oraz ha…
Polish 1.2 KB
2025-10-21 17:52
Lista akcjonariuszy posiadających co najmniej 5% głosów na Nadzwyczajnym Walnym…
Polish 1.3 KB
2025-10-21 17:04
Treść uchwał podjętych przez NWZ Pure Biologics S.A. w dniu 21.10.2025 r.
Polish 218.5 KB
2025-10-21 17:04
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie Pure Biologics S.A…
Polish 775 bytes
2025-10-17 14:29
Zawiadomienie Filip Jeleń
Polish 75.8 KB
2025-10-17 14:29
Zawiadomienie ACRX Investments Limited
Polish 77.7 KB
2025-10-17 14:29
Zawiadomienia akcjonariuszy o zmianie stanu posiadania akcji Spółki - Content (…
Polish 765 bytes
2025-10-15 17:53
Tekst jednolity statutu Spółki
Polish 351.5 KB

Automate Your Workflow. Get a real-time feed of all Pure Biologics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pure Biologics S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pure Biologics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bone Biologics Corp Logo
Develops a protein-based bone graft substitute for spinal fusion procedures.
United States of America
BBLG
Bonyf N.V. Logo
Develops medical devices for oral, dental, orthodontic, and dermatological care.
Belgium
MLBON
Boryung Corporation Logo
A healthcare company developing pharmaceuticals and investing in health sector innovation.
South Korea
003850
Bosnalijek d.d. Sarajevo Logo
Develops, manufactures, and exports a wide range of pharmaceutical products.
Bosnia and Herzegovina
BSNL
Boule Diagnostics Logo
Provider of hematology systems for decentralized human and veterinary markets.
Sweden
BOUL
Boundless Bio, Inc. Logo
Clinical-stage oncology company targeting ecDNA in oncogene amplified cancers.
United States of America
BOLD
BridgeBio Oncology Therapeutics, Inc. Logo
Clinical-stage biopharma developing inhibitors for genetically driven cancers.
United States of America
BBOT
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and cancers.
United States of America
BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Develops selective serotonin agonists for neurological and psychiatric disorders.
United States of America
DRUG
A clinical-stage biopharma company developing cancer immunotherapies and cell therapies.
Japan
4594

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.